Q-omics provides the consensus-scored CAPN14 profile across patient tissues and cancer cell-line models. CAPN14 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, CAPN14 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, CAPN14 RNA expression shows 18,387 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SCLC, HNSC, and UVM as cancer lineages where CAPN14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAPN14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAPN14 survival associations across molecular data types. CAPN14 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAPN14 RNA expression–survival associations across cancer types. High CAPN14 expression shows unfavorable associations in KIRP, UVM and BRCA, but favorable associations in SCLC, KIRC and BLCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for CAPN14 RNA expression.
This table summarizes CAPN14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CAPN14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAPN14 shows lower tumor expression in HNSC and KICH and higher tumor expression in LUAD, COAD, LUSC and LIHC. The HNSC box plot shows higher CAPN14 RNA expression in normal versus tumor tissue (log2 FC = −3.312, t-test p < 0.001).
This table shows molecular features associated with CAPN14 in patient tissues and cancer cell lines. In patient samples, CAPN14 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CAPN14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
